UV-A1 for Keloid

Asawanonda, Pravit; Khoo, Lawrence; Fitzpatrick, Thomas B.; Taylor, Charles R.

doi:10.1001/archderm.135.3.348

Cited by 41 publications

(30 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Verapamil cream applied on the keloid scar appears to prevent rebound scarring from intralesional injections. 46 Other agents that may enhance scar degradation are calmodulin inhibitors (e.g. trifluoroperazin) and protein C kinas inhibitors (tamoxifen).…”

Section: Therapies Under Investigationmentioning

confidence: 99%

“…These agents are promising to treat non inflamed older scar with no active remodeling. 46 Imiquimod is an immune response modulator through increasing expression of tissue necrotic factor alpha, gamma and alpha interferons (IFN-a, g), and interleukin 1, 6, 8, 12. 35 In addition, imiquimod also acts as Toll-like receptor (TLR) agonist, 33 and shows promising results in a few reported cases.…”

Section: Therapies Under Investigationmentioning

confidence: 99%

See 1 more Smart Citation

Novel Insights on Understanding of Keloid Scar: Article Review

Mari

Alsabri

Tabal

et al. 2015

Journal of the American College of Clinical Wound Specialists

123

View full text Add to dashboard Cite

Keloid scar, dermal benign fibro-proliferative growth that extends outside the original wound and invades adjacent dermal tissue due to extensive production of extracellular matrix, especially collagen, which caused by over expression of cytokines and growth factors. Although many attempts were made to understand the exact pathophysiology and the molecular abnormalities, the pathogenesis of keloid scar is yet to be determined. Even though there are several treatment options for keloid scars include combination of medical and surgical therapies like combination of surgical removal followed by cryotherapy or intralesional steroid therapy, the reoccurrence rate is still high despite the present treatment. In this review, PubMed, clinical key and Wright State Library web site have been used to investigate any update regarding Keloid disease. We used Keloid, scar formation, hypertrophic scar and collagen as key words. More than 40 articles have been reviewed. This paper reviews literature about keloid scar formation mechanism, the most recent therapeutic options including the ones under research.

show abstract

Section: Therapies Under Investigationmentioning

confidence: 99%

Section: Therapies Under Investigationmentioning

confidence: 99%

Novel Insights on Understanding of Keloid Scar: Article Review

Mari

Alsabri

Tabal

et al. 2015

Journal of the American College of Clinical Wound Specialists

123

View full text Add to dashboard Cite

show abstract

“…Its use has lately been documented mainly in atopic dermatitis [6,7,8], localized scleroderma [9,10] and in lichenoid dermatosis [11]. Other diseases responding to UVA1 phototherapy include keloids [12], urticaria pigmentosa [13] and systemic lupus erythematosus [14]. The value of using UVA1 in the treatment of cutaneous lymphomas has also been qualified by several authors [15,16,17,18].…”

Section: Introductionmentioning

confidence: 99%

Granulomatous Slack Skin Responds to UVA1 Phototherapy

et al. 2009

View full text Add to dashboard Cite

Granulomatous slack skin (GSS) is an extremely rare disorder within the group of cutaneous T cell lymphomas (CTCL). Ultraviolet A1 (UVA1) phototherapy has previously been reported to be useful in the treatment of CTCL such as mycosis fungoides. We report a 35-year-old Caucasian male with GSS treated with UVA1 phototherapy starting at 20 J/cm² UVA1 3 times a week and subsequently increased in increments of 5 J/cm² to a medium-range dose of 50 J/cm² per session. The patient underwent a total of 45 sessions with a cumulative dose of 1,495 J/cm² UVA1 without any adverse events. At the conclusion of UVA1 phototherapy, a decrease in erythema and skin thickness was observed which was most prominent in the periphery of the lesion in the right groin area. A follow-up 12 months after phototherapy showed continued treatment benefit. To our knowledge, this is the first report describing the successful use of UVA1 (340–400 nm) phototherapy in a patient with GSS.

show abstract

“…The efficacy of this small portable, inexpensive LED light source on treating fibrosis tissue is comparable to a large UV-A1 machine. 18 Various UV-A1 sources are available, such as fluorescent lamp cubicles which allow only low (10e30 J/cm 2 ) to medium (40e70 J/cm 2 ) individual treatment doses to be administered. High-output metal halide sources allow high doses (up to 130 J/cm 2 ) for a single treatment session.…”

Section: Discussionmentioning

confidence: 99%

“…A higher UV-A1 dose is also required for treating keloid. 18 The higher dose required for treating fibrosing diseases suggests the existence of one effective threshold dose of UV-A1 irradiation, probably higher than 2250 J/cm 2 . The thicker collagenous tissue may need a higher light dose to achieve therapeutic results.…”

Section: Discussionmentioning

confidence: 99%

Portable ultraviolet light A1 light source to treat hypertrophic scar

Huang

et al. 2015

Dermatologica Sinica

View full text Add to dashboard Cite

a b s t r a c tBackground/Objectives: Recently, fibrotic diseases such as hypertrophic scar, keloid, and scleroderma have been treated with UV-A1 radiation with encouraging results. However, conventional UV light sources are bulky and expensive. In this study, we aimed to verify the effectiveness of a portable UV-A1 radiation device in treating hypertrophic scars. Materials and methods: A light-emitting diode array that emitted 365 ± 5 nm (UV-A1) was used to irradiate fibroblasts and hypertrophic scar in a rabbit model. Results: In cell cultures, UV-A1 light exposure inhibited post-wound cell migration and reduced the total amount of soluble collagen production in fibroblasts. Type I collagenase production and its activity increased after treatment. On the rabbit ear, UV-A1 light irradiation reduced the thickness of hypertrophic scars, confirming the antifibrotic effect in vivo. Conclusion: These results support the potential of a portable UV-A1 light device in treating hypertrophic scar.

show abstract

UV-A1 for Keloid

Cited by 41 publications

References 7 publications

Novel Insights on Understanding of Keloid Scar: Article Review

Novel Insights on Understanding of Keloid Scar: Article Review

Granulomatous Slack Skin Responds to UVA1 Phototherapy

Portable ultraviolet light A1 light source to treat hypertrophic scar

Contact Info

Product

Resources

About